

> CORPORATE INFORMATION

Palau Pharma, S.A. (“Palau”) is a product-driven biopharmaceutical company focused on the research and development of revolutionary and differentiated new medicines that are designed to address the unmet needs of patients suffering from inflammatory and autoimmune diseases.

> A Strategy Designed for Solid Results

Palau’s core business model is based on identifying unmet medical needs in order to develop novel drugs through Phase IIa clinical trials. At that point, decisions are made on a case-by-case basis whether to keep the development in-house or partner the compound for further late stage development and commercialization.

Our R&D strategy is focused on developing “best-in-class” or “first-in-class” drugs that modulate the activity of validated targets with established preclinical or clinical proof-of-concept. Based on a unique and high-quality cost-effective structure, our final objective is to achieve early positive differentiation from our competitor’s molecules by addressing their limitations and designing a clear, focused and fast path to commercial success.

Our primary focus is on inflammatory and autoimmune diseases, however, we consider other therapeutic fields, such as oncology, where there are synergies and commercial opportunities with existing development projects.



> Every Partnership Is a Solid Commitment

At Palau, partnering plays a strong role in both our business model and our development philosophy. We believe that the key to success is establishing successful partnerships that are driven by strong commitment, close collaboration and transparent communication.

We have demonstrated above-average success rates in each project we have pursued and our business model has been strongly validated through partnering agreements with a broad range of companies, including GlaxoSmithKline, Schering-Plough, Affectis Pharmaceuticals, Vétoquinol and Iberhospitex, amongst others.

We are actively building networks and pursuing innovative, creative and value-driven alliances with pharmaceutical and biotechnology companies around the world. Our goal is to create value for all stakeholders in the development of new drugs, including patients and health care professionals.

At a glance

- Founded: November 2006
- Spin-out from Grupo Uriach
- Two products in the market
- Over €50 M raised in several rounds of financing

Management






- **Ignacio Faus**
Chief Executive Officer
- **Jordi Xaus**
Chief Scientific Officer
- **Heidi Sisniega**
Chief Business Officer

Shareholders

- Grupo Uriach
- Caixa Catalunya
- Caja Duero
- Andosins Capital
- Najeti Capital
- Senior Management



> We Are Making Solid Progress

Project	Indication	Discovery	Preclin.	Phase I	Phase II	Phase III	Market	Partner
ACTIVE [®] and IRIST [®] STENTS	Coronary Restenosis	█	█	█	█	█	█	
CIMALGEX [®]	Inflammatory diseases, pain (veterinary product)	█	█	█	█	█	█	
Albaconazole	Fungal infections	█	█	█	█	█		
Cimicoxib	Depression	█	█	█	█			
Dersalazine sodium	Ulcerative colitis	█	█	█	█			
UR-63325 (H ₄ R antagonist)	Asthma, allergic rhinitis	█	█	█				
UR-13870 (p38 MAPK Inhibitor)	Neuropathic pain, rheumatoid arthritis	█	█	█				
UR-65318 (H ₄ R antagonist)	Atopic dermatitis	█	█					
UR-67767 (Jak inhibitor)	Inflammatory, autoimmune diseases	█	█					
Neogenius Pharma (new target)	Inflammatory diseases	█						
Dendria (new target)	Neuroinflammatory diseases	█						

- > **ACTIVE[®] and IRIST[®] Stents** – Drug eluting coronary stents coated with paclitaxel (ACTIVE[®]) or simvastatin (IRIST[®]), using a polymer containing the antiplatelet agent triflusal. Marketed. Partnered with Iberhospitex (Spain).
- > **CIMALGEX[®]** – Selective cyclooxygenase-2 inhibitor for the treatment of inflammation and pain conditions in companion animals. Marketed. Partnered with Vétoquinol Veterinary Pharmaceuticals (France).
- > **Albaconazole** – Oral broad-spectrum antifungal agent. Phase Ib/IIa clinical trials complete for tinea pedis. Phase IIa clinical trials complete for vulvovaginal candidiasis and Phase IIb clinical trials complete for onychomycosis.
- > **Cimicoxib** – Selective cyclooxygenase-2 inhibitor for the oral treatment of depression. Phase IIa clinical trials complete. Partnered with Affectis Pharmaceuticals (Germany).
- > **Dersalazine sodium** – New chemical entity indicated for the oral treatment of moderate to severe ulcerative colitis. Phase IIa clinical trials complete.
- > **UR-13870** – p38 MAP kinase inhibitor for the treatment of inflammatory and autoimmune diseases such as neuropathic pain and rheumatoid arthritis. Phase Ib clinical trials.
- > **UR-63325** – Novel histamine H₄ receptor antagonist for the oral treatment of allergic respiratory diseases (asthma and allergic rhinitis). Phase Ib/IIa clinical trials.
- > **UR-65318** – Small molecule antagonist of the histamine H₄ receptor for the treatment of atopic dermatitis. Preclinical testing.
- > **UR-67767** – Balanced Janus Kinase (Jak) selective inhibitor for the treatment of inflammatory and autoimmune diseases. Preclinical testing.
- > **Neogenius Pharma** – Drug Discovery program focused on the identification of innovative molecules to treat inflammatory pain. Early discovery stage. Partnered with Draconis Pharma within a consortium with Amiral and Esteve (Spain).
- > **Dendria** – Drug Discovery program focused on the identification of new molecules to treat neuroinflammatory diseases. Early discovery stage. Partnered with Draconis Pharma within a consortium with Noscira and Faes (Spain), and nine other Spanish biotechnology companies.

Contacts

For further information on Palau Pharma and its products, please visit

www.palaupharma.com

or contact:

Heidi Sisniega
Chief Business Officer
P: +34.93.863.0483
E: hsisniega@palaupharma.com

Palau Pharma, S.A.
Pol. Ind. Riera de Caldes
Av. Camí Reial, 51-57
08184 Palau-solità i Plegamans
(Barcelona), Spain